These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 34292533)

  • 1. Amivantamab: First Approval.
    Syed YY
    Drugs; 2021 Jul; 81(11):1349-1353. PubMed ID: 34292533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of
    Yun J; Lee SH; Kim SY; Jeong SY; Kim JH; Pyo KH; Park CW; Heo SG; Yun MR; Lim S; Lim SM; Hong MH; Kim HR; Thayu M; Curtin JC; Knoblauch RE; Lorenzi MV; Roshak A; Cho BC
    Cancer Discov; 2020 Aug; 10(8):1194-1209. PubMed ID: 32414908
    [No Abstract]   [Full Text] [Related]  

  • 3. MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.
    Cho BC; Felip E; Hayashi H; Thomas M; Lu S; Besse B; Sun T; Martinez M; Sethi SN; Shreeve SM; Spira AI
    Future Oncol; 2022 Feb; 18(6):639-647. PubMed ID: 34911336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amivantamab: a monoclonal EGFR-MET bispecific antibody for EGFR exon 20 insertion in non-small cell lung cancer.
    Xie Y; Lu Q; Wang JQ; Bo L; Ashby CR; Chen ZS
    Drugs Today (Barc); 2022 Aug; 58(8):389-398. PubMed ID: 35983925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Global Regulatory Initiatives Deliver Accelerated Approval of the First Bispecific Therapeutic Monoclonal Antibody for Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2021 Sep; 27():e934854. PubMed ID: 34565792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
    Park K; Haura EB; Leighl NB; Mitchell P; Shu CA; Girard N; Viteri S; Han JY; Kim SW; Lee CK; Sabari JK; Spira AI; Yang TY; Kim DW; Lee KH; Sanborn RE; Trigo J; Goto K; Lee JS; Yang JC; Govindan R; Bauml JM; Garrido P; Krebs MG; Reckamp KL; Xie J; Curtin JC; Haddish-Berhane N; Roshak A; Millington D; Lorenzini P; Thayu M; Knoblauch RE; Cho BC
    J Clin Oncol; 2021 Oct; 39(30):3391-3402. PubMed ID: 34339292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET.
    Neijssen J; Cardoso RMF; Chevalier KM; Wiegman L; Valerius T; Anderson GM; Moores SL; Schuurman J; Parren PWHI; Strohl WR; Chiu ML
    J Biol Chem; 2021; 296():100641. PubMed ID: 33839159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    Chon K; Larkins E; Chatterjee S; Mishra-Kalyani PS; Aungst S; Wearne E; Subramaniam S; Li Y; Liu J; Sun J; Charlab R; Zhao H; Saritas-Yildirim B; Bikkavilli RK; Ghosh S; Philip R; Beaver JA; Singh H
    Clin Cancer Res; 2023 Sep; 29(17):3262-3266. PubMed ID: 37022784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The development of amivantamab for the treatment of non-small cell lung cancer.
    Brazel D; Nagasaka M
    Respir Res; 2023 Oct; 24(1):256. PubMed ID: 37880647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amivantamab plus Chemotherapy in NSCLC with
    Zhou C; Tang KJ; Cho BC; Liu B; Paz-Ares L; Cheng S; Kitazono S; Thiagarajan M; Goldman JW; Sabari JK; Sanborn RE; Mansfield AS; Hung JY; Boyer M; Popat S; Mourão Dias J; Felip E; Majem M; Gumus M; Kim SW; Ono A; Xie J; Bhattacharya A; Agrawal T; Shreeve SM; Knoblauch RE; Park K; Girard N;
    N Engl J Med; 2023 Nov; 389(22):2039-2051. PubMed ID: 37870976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.
    Minchom A; Viteri S; Bazhenova L; Gadgeel SM; Ou SI; Trigo J; Bauml JM; Backenroth D; Bhattacharya A; Li T; Mahadevia P; Girard N
    Lung Cancer; 2022 Jun; 168():74-82. PubMed ID: 35597172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of the Effcacy and Safety of Amivantamab in Non-small Cell Lung Cancer 
Patients with EGFR/MET Gene Abnormalities: A Single Center's Experience].
    Wang J; Chi Y; Chen H; Jia B; Zhai X; Ma M; Li J; Zhuo M
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):493-500. PubMed ID: 35899447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.
    Chouaid C; Bosquet L; Girard N; Kron A; Scheffler M; Griesinger F; Sebastian M; Trigo J; Viteri S; Knott C; Rodrigues B; Rahhali N; Cabrieto J; Diels J; Perualila NJ; Schioppa CA; Sermon J; Toueg R; Erdmann N; Mielke J; Nematian-Samani M; Martin-Fernandez C; Pfaira I; Li T; Mahadevia P; Wolf J
    Adv Ther; 2023 Mar; 40(3):1187-1203. PubMed ID: 36652175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amivantamab for the treatment of
    Vyse S; Huang PH
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):3-16. PubMed ID: 34913823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amivantamab: A New Hope in Targeting Non-small Cell Lung Cancer.
    Billowria K; Das Gupta G; Chawla PA
    Anticancer Agents Med Chem; 2023; 23(2):124-141. PubMed ID: 35616682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer
    Kim TM; Girard N; Low GKM; Zhuo J; Yu DY; Yang Y; Murota M; Lim CTK; Kleinman NJ; Cho BC
    Acta Oncol; 2023 Dec; 62(12):1689-1697. PubMed ID: 37938161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.
    Cho BC; Simi A; Sabari J; Vijayaraghavan S; Moores S; Spira A
    Clin Lung Cancer; 2023 Mar; 24(2):89-97. PubMed ID: 36481319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study.
    Girard N; Park K; Lee SH; Viteri S; Schioppa CA; Diels J; Oguz M; Rodrigues BH; Rahhali N; Sermon J; Ghilotti F; Li T; Thayu M; Knoblauch RE; Mahadevia P; Cho BC
    Cancer Treat Res Commun; 2024; 40():100832. PubMed ID: 39033692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mobocertinib: First Approval.
    Markham A
    Drugs; 2021 Nov; 81(17):2069-2074. PubMed ID: 34716908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy.
    Shah V; McNatty A; Simpson L; Ofori H; Raheem F
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.